UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The ~~the~~ Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~ 25September 3, 2013

MedClean Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-03125

21-0661726

(State or other jurisdiction of

incorporation or organization)

(Commission

file number)

(IRS Employer

Identification No.)

Delaware	000-03125	21-0661726
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification Number)

57 S. Commerce Way, Suite 310

~~57 S Commerce Way, Suite 310~~ Bethlehem, PA PA 18017

(Address of principal executive offices, including zip code)

1(203) 798-~~888-777-4077~~1080

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item 5~~ITEM 1.0201 ~~Departure~~ENTRY ofINTO ~~Directors~~A orMATERIAL ~~Certain~~DEFINITIVE ~~Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~AGREEMENT

~~Resignation~~Effective September 3, 2013, MedClean Technologies, Inc., a Delaware corporation (“MedClean” or the “Company”) (OTC Pink: MCLN) entered into an Agreement and Plan of Merger (“Merger Agreement”), between the ~~Executive~~Company ~~Chairman~~and BioMedical Technology Solutions Holdings, Inc., a Colorado corporation (the “Company” or “BMTS”) (OTC Pink: BMTL). The Merger Agreement, if consummated, would result in BMTS merging with and into MedClean, with MedClean being the surviving corporation (the “Merger”) and with BMTS’s existing subsidiary, BioMedical Technology Solutions, Inc. (“BMTS Sub) surviving as a wholly owned subsidiary of MedClean. Upon consummation of the Merger, all issued and outstanding shares of BMTS common stock will convert into a number of shares of MedClean common stock which will represent, when issued, and after giving effect to the Debt Conversions described below, 60% of the total issued and outstanding shares of MedClean (the “Exchange Ratio”). The Merger will result in a change in control of MedClean. The Merger is subject to any dissenters’ rights of the BMTS and MedClean shareholders.

~~Effective February 25, 2013, Mr. David Laky resigned~~Each ~~from~~party’s ~~his~~obligation ~~position as Executive Chairman of MedClean Technologies, Inc. (the “Company”). Mr. Laky will continue~~ to ~~the~~ ~~serve~~close the ~~Company~~transaction ~~in his capacity as a director. Mr. Lakys’ resignation~~ is ~~not~~subject ~~the result of any disagreement with the Company on any matter relating~~ to the ~~Company’s~~satisfaction ~~operations, policies or practices. Appointment~~ of ~~Chief~~certain ~~Executive~~conditions ~~Officer~~by ~~and Chairman of~~ the ~~Board Effective~~other ~~February 25~~party, ~~2013,~~including in ~~Mr.~~part ~~John~~(i) ~~Accardi~~MedClean ~~was~~filing ~~appointed~~all asdelinquent ~~Chief~~reports ~~Executive~~under ~~Officer~~Section ~~and President of the Company by unanimous vote at~~ 13(a) ~~special meeting~~ of the ~~Board~~Securities ofExchange ~~Directors~~Act of ~~the~~1934, ~~Company~~as ~~(the~~amended, (“~~Board~~Exchange Act”)., ~~Mr.~~including ~~Accardi~~audited ~~has~~and ~~served~~interim asfinancial ~~the~~statements, ~~Company’s Senior~~(ii) ~~Vice~~BMTS ~~President~~completing ~~of Business Development since~~ the ~~year~~preparation ~~2000.~~of ~~Mr.~~two ~~Accardi~~years ~~will~~audited ~~no longer serve as the Company in his capacity~~financial asstatements ~~Senior~~complying ~~Vice~~with ~~President~~Regulation ofS-X ~~Business~~under ~~Development but will move forward with~~ the ~~Company~~Exchange inAct, ~~his~~(iii) ~~newly~~both ~~appointed~~MedClean ~~roles as Chief Executive Officer~~ and ~~President. Effective~~BMTS ~~February~~obtaining ~~25,~~the ~~2013,~~agreements ~~Mr.~~of ~~Jay~~their respective ~~Bendis~~creditors ~~was~~to ~~appointed~~convert assubstantially ~~Chairman~~all ofoutstanding ~~the~~liabilities ~~Board~~to ofshares ~~the Directors~~ of ~~the~~common ~~Company~~stock (the “~~Board~~Debt Conversions”), bywhich ~~unanimous~~Debt ~~vote~~Conversions atwill abe ~~special~~given ~~meeting~~effect ofprior ~~the~~to ~~Board.~~determining ~~Mr.~~the ~~Bendis~~Exchange ~~had~~Ratio, ~~previously~~(iv) ~~served as~~ the ~~Company’s~~approval ~~Chairman~~ of the ~~Board from~~Merger ~~April~~by ~~1, 2011 to September 20, 2012, at which time he temporarily resigned until such time as~~ the ~~Company found a new Chief~~shareholders ~~Executive~~of ~~Officer. John~~both ~~Accardi,~~BMTS ~~age~~and 51MedClean, ~~Chief Executive Officer~~ and ~~President Mr.~~(v) ~~Accardi,~~the ~~age~~preparation ~~51,~~and ~~combines~~effectiveness ~~over 15 years~~ of ~~experience~~a inRegistration ~~sales/marketing~~Statement ~~business~~on ~~development~~Form ~~and~~S-4 ~~senior~~registering ~~management~~for ~~following~~sale 10of ~~years~~the inshares ~~various~~of ~~other~~MedClean ~~roles. Previously,~~common ~~Mr.~~stock ~~Accardi~~issuable ~~had~~to ~~been~~the ~~involved~~BMTS shareholders in ~~numerous other companies within~~ the ~~Hi-Technology~~ ~~space~~Merger, ~~holding~~and ~~positions~~(vi) ~~including~~complete ~~Senior~~and ~~Vice~~satisfactory ~~President~~due diligence ofand ~~Channel~~other ~~Sales,~~conditions ~~Senior~~customary ~~Vice~~in ~~President~~transactions of ~~Worldwide~~this ~~Sales and Regional General Manager/Vice President~~nature. ~~From~~ ~~2008~~Each ~~through~~party ~~January,~~may ~~2013,~~waive ~~Mr.~~any ~~Accardi~~of ~~has served as~~ the ~~Company~~other party’s ~~Senior~~ ~~Vice President of Business Development From 2000 to 2008, Mr. Accardi was Regional Manager for Oracle/Siebel Systems, Inc.,~~obligations athat ~~company~~are ~~involving~~conditions ~~CRM Enterprise Software. From July, 1997~~ to ~~July,~~closing ~~2000, Mr. Accardi was Senior Vice President of World Wide Sales~~ and ~~Support~~proceed ofto ~~Rasterex Software~~closing, ~~Inc.~~however, athere ~~Raster~~can ~~CAD~~be ~~Technology~~no ~~Company~~assurance ~~that~~as ~~focused on Enhanced AutoCad Applications. From August 1994~~ to ~~July~~when ~~1997,~~the ~~Mr.~~transaction ~~Accardi~~can ~~served~~or ~~as Vice President/General Manager of International Channels and Southern Region for~~will ~~Computron~~be ~~Software~~consummated. ~~Mr.~~ ~~Accardi~~For ~~has an undergraduate degree from Champlain College and Fairleigh Dickinson University. Family Relationships Mr. Accardi does not have~~ a ~~family~~complete ~~relationship~~statement ~~with any~~ of the ~~current~~conditions ~~officers~~to orclosing ~~directors of~~ the ~~Company. Related~~transaction, ~~Party~~please ~~Transactions There~~see ~~are~~the nocopy ~~related party transactions reportable under Item 5.02~~ of ~~Form~~the ~~8-K~~Merger ~~and~~Agreement filed ~~Item~~herewith ~~404(a)~~as ofExhibit ~~Regulation S-K~~1. ~~Item 9.~~01 ~~Financial Statements and Exhibits~~A.

Exhibit No.		Description
99.1		Letter of Resignation from David Laky, dated February 25, 2013

Concurrently with the execution of the Merger Agreement, BMTS and MedClean entered into a Management Agreement (“Management Agreement”), whereby pending the closing of the Merger described above, MedClean has retained BMTS as Business Manager of MedClean to perform the day to day business operations of MedClean. A copy of the Management Agreement is filed herewith as Exhibit 1.01 B.

~~SIGNATURES~~ITEM 8.01: OTHER EVENTS

~~Pursuant~~As noted toabove, in connection with the ~~requirements~~contemplated oftransaction, MedClean is engaging its auditors to prepare all delinquent and current financial reports. The Company anticipates that the ~~Securities~~information contained in its pre-merger reports will be negative. ~~Exchange~~Completion ~~Act~~and filing of ~~1934,~~these reports is contingent upon the ~~Registrant~~receipt ~~has~~of ~~duly~~financing ~~caused~~in ~~this~~connection ~~report~~with tothe becontemplated ~~signed~~transaction sufficient onfor ~~its~~payment ~~behalf~~of bythe costs of the ~~undersigned~~preparing ~~hereunto~~and ~~duly~~filing ~~authorized~~the reports.

	MEDCLEAN TECHNOLOGIES, INC.
Date: February 26, 2013	By:	/s/ John Accardi
	Name:	John Accardi
	Title:	Chief Executive Officer

ITEM 9.01: FINANCIAL STATEMENTS AND EXHIBITS

See Item 8.01 above.

EXHIBITS

Item		Title

1.01 A		Agreement and Plan of Merger dated effective September 3, 2013

1.01 B		Management Agreement dated September 3, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MedClean Technologies, Inc.

Date: September 10, 2013	By:	/s/ John R. Accardi
		John R. Accardi, President and Chief Executive Officer

Filing Compare · MedClean Technologies, Inc.